Foundayo FDA approval was officially announced today, marking a transformative moment for millions of Americans living with obesity. Eli Lilly and Company (NYSE: LLY) confirmed that the U.S. Food and Drug Administration (FDA) has cleared Foundayo™ (orforglipron), the first and only non-peptide oral GLP-1 receptor agonist for chronic weight management.
Unlike previous oral GLP-1 treatments that require strict fasting and water limitations, the Foundayo FDA approval introduces a medication that can be taken at any time of day, with or without food. This flexibility is expected to significantly improve patient adherence and accessibility in the rapidly evolving obesity care market.
The Significance of the Foundayo FDA Approval for Patients
The Foundayo FDA approval is rooted in the successful results of the ATTAIN-1 and ATTAIN-2 Phase 3 clinical trials. In these studies, participants taking the highest dose of orforglipron lost an average of 27.3 pounds (12.4% of their body weight) over 72 weeks, compared to just 2.2 pounds in the placebo group.
People living with obesity need treatment options that meet them where they are,
With the Foundayo FDA approval, we finally have an oral option that addresses both clinical efficacy and the practical daily challenges patients face.
Deborah Horn
Read More Eli Lilly’s Oral Weight-Loss Drug Orforglipron Shows Promising Results in Phase 3 Trial
Foundayo FDA Approval: Pricing and Availability
Lilly has moved quickly following the Foundayo FDA approval to ensure the medication reaches patients without delay. Key details regarding its launch include:
- Launch Date: Shipping is scheduled to begin on April 6, 2026.
- Distribution: Available via the LillyDirect® digital pharmacy and retail pharmacies nationwide.
- Cost: Eligible patients with commercial insurance may pay as little as $25 per month. For those without coverage, self-pay options start at $149 per month for the starting dose.
Comparing Foundayo to Existing GLP-1 Therapies
Before the Foundayo FDA approval, patients seeking GLP-1 therapy were largely limited to weekly injections or oral options with complex dosing requirements. Orforglipron is a small-molecule, non-peptide drug, meaning it is not broken down by stomach acid as easily as peptide-based drugs like semaglutide. This chemical structure is what allows Foundayo to be taken without the typical 30-minute fasting window.
Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN
The FDA has granted traditional approval to Novartis' Fabhalta (iptacopan) — the first complement inhibitor shown to significantly slow kidney function decline in adults with […]
LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C
The LIPFENDRA FDA approval makes Merck's enlicitide the first once-daily oral PCSK9 inhibitor cleared to lower LDL-C in adults with hypercholesterolemia, including HeFH. Phase 3 […]
GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline
GSK has completed its $10.6 billion acquisition of Nuvalent, Inc., gaining three targeted lung cancer therapies, including zidesamtinib and neladalkib, both currently under FDA review […]
Safety and Regulatory Milestones
The Foundayo FDA approval also sets a regulatory record. The drug was cleared under the FDA’s new Commissioner’s National Priority Voucher (CNPV) program, resulting in one of the fastest approvals for a new molecular entity in over two decades.
According to the official FDA Press Announcement, the agency prioritized the review due to the high national priority of treating obesity-related comorbidities such as hypertension and cardiovascular disease. Like other medications in its class, Foundayo includes warnings regarding gastrointestinal side effects and thyroid C-cell tumors.
